Trial Profile
A Swedish nationwide pharmaco-epidemiological and genetic study to assess long-term safety and effectiveness of natalizumab in a real-world setting
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 28 Nov 2023
Price :
$35
*
At a glance
- Drugs Natalizumab (Primary)
- Indications Multiple sclerosis
- Focus Adverse reactions; Therapeutic Use
- Acronyms IMSE 1
- 13 Oct 2023 Results (n=4011; data from Aug 2006 until Mar 2023) assessing drug survival presented at the 9th Triennial joint meeting of Americas Committee for Treatment and Research in Multiple Sclerosis and the European Committee for Treatment and Research in Multiple Sclerosis
- 12 Oct 2018 Results (n=2306) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis.
- 12 Oct 2018 Results (n=3052) presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis